Navigation Links
H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
Date:11/26/2012

CAMBRIDGE, Mass., Nov. 26, 2012 /PRNewswire/ -- Following a productive first year of headcount growth and scientific advancement, H3 Biomedicine Inc. (H3), a biopharmaceutical company specializing in the discovery and development of oncology treatments, announced today that it has completed an expansion of its headquarters and laboratory facilities in Cambridge, Massachusetts.  The increase more than doubles the company's original space to approximately 48,000 square feet, including new state-of-the-art laboratories, offices and meeting rooms.  The expansion will support an anticipated staff of 75 employees by the end of 2013, an increase in H3 Biomedicine's employee base of 29 in 2011. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

"While we remain an early-stage, research-focused company, our rapid growth this year marks a significant step toward developing novel oncology drug candidates, and, ultimately, expediting the delivery of new therapies to the patients who need them," said Markus Warmuth, M.D., President and Chief Executive Officer of H3 Biomedicine.  "Our unique corporate culture encourages science-driven work and access to shared resources. We are fortunate to attract top talent while operating in the Cambridge area, where the technical expertise and entrepreneurial spirit are a strong fit for our organization."

In December 2011, H3 Biomedicine opened its headquarters in Cambridge with 24,000 square feet of working space. Eisai Co. Ltd., a research-based human health care (hhc) company, pledged up to $200 million in research funding to H3 Biomedicine and will provide additional support for the company's clinical development programs, including access to many of Eisai's drug development capabilities.

"Eisai's commitment is based on our recognition that H3 Biomedicine possesses strong fundamentals in their science programs and innovative approach toward cancer treatment development," said Haruo Naito, Eisai Co., Ltd. President and CEO. "We are pleased that in this past year alone, the strong growth of their research-based initiatives has brought us closer to the vision of realizing the potential of personalized medicine."

Progress on Major Programs, Collaborations, Contribute to Expansion
H3 Biomedicine's leadership attributes the accelerated growth in large part to the dedication of its scientists, including the bioinformatics team that is driving its cancer genome mining work. These efforts aim to identify and validate recurrent gene mutations that are potential targets for drug therapies—the crucial first step in the company's mission to develop a library of novel oncology candidates for clinical testing. Currently, H3 Biomedicine's lead program is designed to develop drugs that target the gene SF3b1. Several recent publications have implicated mutations in this gene in blood-related malignant conditions, such as myelodysplastic syndromes and chronic lymphocytic leukemia, as well as solid tumors like those associated with skin, breast and pancreatic cancers.  H3 plans to utilize its new facilities to expand operations in pharmacokinetics and preclinical efficacy studies—components crucial to H3's lead program. 

H3 Biomedicine's world-class facilities and technology have also enabled several key collaborations in 2012, including projects with Compendia Bioscience and Horizon Discovery LTD.  "These alliances have tremendous synergy with our own scientific programs," continued Warmuth, "and our expanded facilities will enable us to fulfill the programmatic requirements of additional partnerships in which we participate."

About H3 Biomedicine Inc. 
H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit http://www.H3biomedicine.com for more information.

About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. Eisai employs approximately 11,000 employees worldwide.


'/>"/>
SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. A 300 Million Euro Boost for Biomedicine in Berlin
2. Medical Marijuana, Inc. Portfolio Company CanChew BioTechnologies Inc. Updates and Expands Free Product Trial
3. Why Texas is #1 in Business: Local BioTech Company Expands
4. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
5. Rosetta Genomics Expands Management Team, Laboratory Capacities and Commercial Operations
6. Elsevier Expands Access to Digital Offerings Through Collaboration with Follett
7. BioStorage Technologies Expands its Service Offering to Include Advanced Bioprocessing Solutions
8. Celltex Therapeutics Corporation Expands Laboratory Operations And Adds Depth To Its Management Team
9. Inspiration Biopharmaceuticals Expands Industry Expertise with Five New Executive Hires
10. Medtech Expands Nursing Education Opportunities In Florida
11. BioNeutral Group Expands The Testing Of Its Ygiene Sterilant Against Anthrax Spores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... Wausau, WI (PRWEB) , ... June 23, 2016 ... ... probiotic supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, ... supplements for over 35 years, is proud to add Target to its list ...
(Date:6/23/2016)... 2016 Houston Methodist Willowbrook Hospital has ... Association to serve as their official health care ... Willowbrook will provide sponsorship support, athletic training services, ... coaches, volunteers, athletes and families. "We ... Association and to bring Houston Methodist quality services ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... March 22, 2016 ... Sensors Market for Consumer Industry by Type (Image, ... Application (Communication & IT, Entertainment, Home Appliances, ... Forecast to 2022", published by MarketsandMarkets, the ... to reach USD 26.76 Billion by 2022, ...
(Date:3/18/2016)... , March 18, 2016 --> ... of Biometrics, ICT, Manned & Unmanned Vehicles, Physical infrastructure and ... security companies in the border security market and the continuing ... and Europe has led visiongain to ... improved success. --> defence & security companies ...
Breaking Biology News(10 mins):